Top of mind for Mylan ($MYL) may be fending off an unsolicited $40 billion buyout offer from competitor Teva ($TEVA), but it still has to take care of business as usual. Right now that includes recalling 8 lots of injectable cancer drugs, most of them manufactured for Pfizer ($PFE), after particulate was discovered in vials. More from FiercePharmaManufacturing